Buyers in the Circulating Tumor Cells market choose across consumables, instruments and regulatory pathways, and adoption depends on where tests fit into care. Polaris Market Research values the market at USD 14.15 billion in 2025 and reports a CAGR of 13.8% from 2026 to 2034, reaching a projected USD 45.13 billion by 2034. This article looks at product demand, clinical use, regulation and the end users driving adoption.

Kits and Reagents Anchor Product Demand

The kits and reagents segment held the largest product share, 41.6%, in 2025, as these products are integral to detecting and enriching CTCs in blood samples. They serve both clinical and research applications, allowing laboratories and providers to test with high accuracy and reliability, and ongoing advances improve sensitivity and ease of use. The report links the segment's lead to a repeat-purchase, high-usage consumable model. The product range also includes blood collection tubes and devices or systems.

High-Throughput Cancer Diagnostics and Automation

The devices or systems segment is projected to register the highest product CAGR, 15.4%, owing to increasing adoption of automated systems for CTC isolation, detection and analysis, such as microfluidic devices and immunomagnetic separation tools. Automation and high-throughput cancer diagnostics are playing a major role in new isolation and detection technologies. Automated approaches reduce the labor and time needed to process samples and minimize human error, while high-throughput platforms enable large-scale research and high-volume clinical testing. The report adds that these solutions offer cost benefits by improving laboratory efficiency, supporting adoption of high-throughput cancer diagnostics worldwide.

Metastatic Cancer Monitoring in Practice

Metastatic cancer monitoring is a central clinical use. CTC applications enable real-time, minimally invasive assessment of disease burden, treatment response and progression risk for breast, colorectal and prostate tumors. Enumerating CTCs in serial samples allows evaluation of therapy: a decrease in CTC count indicates improved survival, while stable or increased counts are associated with treatment resistance or relapse.

Menarini Silicon Biosystems' CellSearch is the platform highlighted for this use. The regulatory table describes it as the only FDA-cleared CTC enumeration system, with 510(k) clearances for metastatic breast (2004), colorectal (2007) and prostate cancer (2008), intended as adjunctive monitoring rather than a standalone diagnostic. ANGLE's Parsortix PC1 System is a CE-marked and FDA-cleared CTC isolation device used for genomic and proteomic profiling across tumor types, and Epic Sciences' DefineMBC analyzes CTCs and cell-free DNA to provide insight into metastatic breast cancer. Used well, metastatic cancer monitoring can help where tissue biopsy is unsuitable.

𝐁𝐫𝐨𝐰𝐬𝐞 𝐌𝐨𝐫𝐞 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬:

https://www.polarismarketresearch.com/industry-analysis/circulating-tumor-cells-market 

Companion Diagnostics and Regulatory Reality

CTCs can support companion diagnostics by identifying tumor biomarkers and genetic changes that may help determine whether a patient is suitable for a specific targeted therapy, and they can support treatment monitoring. The report is clear about the current regulatory position, however: there are no FDA-approved CTC-based companion diagnostics to date. Laboratory-developed tests require CLIA compliance and biomarker confirmation through FDA-cleared or approved tests when used for therapy selection.

Other frameworks apply as well. CTC systems are classified as Class II under 21 CFR 866.6020, risk management follows ISO 14971, and devices marketed in Europe require CE marking under IVDR (EU) 2017/746 with clinical evidence and post-market surveillance.

Hospitals and Clinics Lead End-Use Adoption

The hospitals and clinics segment held the largest end-use share, 48.9%, in 2025, owing to rising adoption of CTC-based technologies for cancer diagnosis, monitoring and treatment planning in clinical settings. The clinical application segment led with a 66.4% share, and blood was the leading specimen at 68.7% because it is accessible and supported by established methods. Hospitals and clinics benefit from continuous advances that allow more accurate real-time detection and monitoring.

Other end users are expanding quickly. Diagnostic centers are expected to register a CAGR of 15.6%, and biopharmaceutical companies a CAGR of 18.15%, driven by investment in cancer drug development and personalized therapies. Hospital laboratories and specialized cancer centers are adopting CTC tests to meet growing demand for companion diagnostics and personalized treatment initiatives.

Regional Drivers

North America held a 42.6% share in 2025, supported by a mature clinical trial ecosystem, favorable reimbursement for molecular diagnostics and high adoption of advanced diagnostics. Asia Pacific is expected to register a CAGR of 16.2%, driven by rising cancer incidence and expanding healthcare infrastructure. Latin America is expected at 15.2%, Europe at 12.7% and the Middle East & Africa at 12.1%.

Recent Developments and Key Players

In May 2026, CellBxHealth collaborated with AdventHealth to use its Parsortix CTC platform in two multi-center studies advancing minimally invasive cancer monitoring. In August 2025, ANGLE plc entered a collaboration with Myriad Genetics to enable use of Parsortix-derived CTC DNA with Myriad's existing tissue-based diagnostic tests.

Key players include AngioDynamics, Apocell Inc., Biolidics Limited, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, CellBxHealth plc, Circulogix, Epigenomics AG, Fluxion Biosciences, Greiner Bio-One, Illumina, Inc., Menarini Silicon Biosystems, Miltenyi Biotec GmbH, Natera, Inc., QIAGEN N.V., ScreenCell, Sysmex Corporation, Sysmex Inostics GmbH and Thermo Fisher Scientific Inc.

Conclusion

Demand in the Circulating Tumor Cells market is anchored by kits and reagents, supported by automation and high-throughput cancer diagnostics, and led in practice by hospitals and clinics. Clinical value is clearest in metastatic cancer monitoring, while companion diagnostics remain an evolving regulatory frontier.

More Trending Latest Reports By Polaris Market Research:

Flooring Market

Maritime Patrol Aircraft Market

Engineered Stone Market

Microgreens Market

AI Integration Platform Market

High Purity Silica Sand for Solar Cell Market

Gypsum Board Market

Home Healthcare Market

Semaglutide Market